^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Ocrevus (ocrelizumab)
i
Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Biogen, Roche
Drug class:
CD20 inhibitor
Related drugs:
24h
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (clinicaltrials.gov)
P3, N=152, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=444 --> 152
Enrollment closed • Enrollment change
|
Ocrevus (ocrelizumab)
5d
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap. (PubMed, Clin Pharmacol Ther)
We summarize pivotal translational inflection points, from rituximab extension beyond lymphoma to approvals of ocrelizumab, ofatumumab, ublituximab, and inebilizumab in neuroimmunology. We further review plasma cell-directed and T-cell-engaging strategies for deep immune resets in refractory disease, while clarifying implications for trial design, long-term safety, and implementation. Finally, we introduce a model-informed roadmap integrating population PK/PD, exposure-response, and quantitative systems pharmacology to optimize indication selection, patient enrichment, and dose/regimen design-supporting confident extrapolation rather than empiricism.
Review • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)
8d
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies (clinicaltrials.gov)
P=N/A, N=1178, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting
Enrollment closed
|
fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
15d
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus (clinicaltrials.gov)
P1, N=222, Not yet recruiting, Polpharma Biologics International AG
New P1 trial
|
Ocrevus (ocrelizumab)
22d
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations (clinicaltrials.gov)
P1, N=180, Active, not recruiting, R-Pharm
New P1 trial
|
Ocrevus (ocrelizumab)
1m
Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
P2, N=360, Recruiting, Hoffmann-La Roche
Trial initiation date
|
Ocrevus (ocrelizumab)
1m
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis (clinicaltrials.gov)
P4, N=50, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting
Enrollment open
|
Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab)
1m
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients (clinicaltrials.gov)
P=N/A, N=2604, Completed, Novartis Pharmaceuticals
New trial • HEOR • Real-world evidence
|
Ocrevus (ocrelizumab)
1m
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (clinicaltrials.gov)
P3, N=360, Recruiting, Novartis Pharmaceuticals | N=215 --> 360
Enrollment change • Head-to-Head
|
Rhapsido (remibrutinib) • Ocrevus (ocrelizumab)
1m
20230309: A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis (2024-512914-16-00)
P2/3, N=375, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Ocrevus (ocrelizumab)
2ms
Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
P2, N=360, Recruiting, Hoffmann-La Roche | N=235 --> 360
Enrollment change • Trial initiation date
|
Ocrevus (ocrelizumab)
2ms
OPA: Ocrelizumab for Psychosis by Autoimmunity (clinicaltrials.gov)
P1/2, N=40, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Jun 2025 --> Jun 2028
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
Share via
